Hypouricemic effects of acacetin and 4,5-o-dicaffeoylquinic acid methyl ester on serum uric acid levels in potassium oxonate-pretreated rats.
The effects of acacetin (1) and 4,5-O-dicaffeoylquinic acid methyl ester (2), compounds contained in the flowers of Chrysanthemum sinense SABINE, on the serum uric acid level were investigated using the rats pretreated with the uricase inhibitor potassium oxonate as an animal model for hyperuricemia. When administered per orally at doses of 20 and 50 mg/kg, 1 reduced the serum uric acid level by 49.9 and 63.9%, respectively and 2 reduced the level by 31.2 and 44.4%, respectively. On the other hand, when the same doses were given intraperitoneally, both of compounds also exhibited a dose-dependent and more marked reduction of the serum uric acid level (% reduction at 20 and 50 mg/kg were 63.0 and 95.1% in 1, respectively and 66.9 and 86.5% in 2, respectively). Furthermore, the compounds 1 and 2 inhibited the rat liver xanthine oxidase activity with IC(50) values of 2.22 muM and 5.27 muM, respectively. These results demonstrated the hypouricemic action of 1 and 2, which may be attributable to their xanthine oxidase inhibitory activity.
Nguyen
Mai Thanh Thi
MT
Division of Natural Products Chemistry, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630-Sugitani, Toyama 930-0194, Japan.
Awale
Suresh
S
Tezuka
Yasuhiro
Y
Shi
Liying
L
Zaidi
Syed Faisal Haider
SF
Ueda
Jun-ya
JY
Tran
Quan Le
QL
Murakami
Yukihisa
Y
Matsumoto
Kinzo
K
Kadota
Shigetoshi
S
D000284:Administration, Oral; D000493:Allopurinol / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D031202:Chrysanthemum; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004952:Esters / Q000494:pharmacology / Q000627:therapeutic use*; D047309:Flavones / Q000494:pharmacology / Q000627:therapeutic use*; D033461:Hyperuricemia / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D020128:Inhibitory Concentration 50; D007274:Injections, Intraperitoneal; D008099:Liver / Q000737:chemistry / Q000187:drug effects; D008297:Male; D010094:Oxonic Acid; D011801:Quinic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014527:Uric Acid / Q000037:antagonists & inhibitors* / Q000097:blood; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use
C508224:4,5-o-dicaffeoylquinic acid methyl ester; D004952:Esters; D047309:Flavones; D011801:Quinic Acid; D014527:Uric Acid; C489337:potassium oxonate; D010094:Oxonic Acid; D000493:Allopurinol; D014969:Xanthine Oxidase; C023717:acacetin